Search
GLP-1 Clinical Trials
A collection of 61 research studies where GLP-1 is the intervention. These studies are located in the United States. GLP-1 is used for conditions such as Obesity, Type 2 Diabetes and Myocardial Infarction.
37 - 48 of 61
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
Completed
The purpose of this study is to identify and evaluate the event rate of the composite endpoint of all-cause mortality (ACM) or hospitalization for heart failure (HF) for participants with Type 2 Diabetes mellitus (T2DM) and established cardiovascular (CV) disease among new users of sodium-glucose co-transporter 2 inhibitor (SGLT2i) as compared with new users of non-SGLT2i anti-hyperglycemic agent (AHA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/17/2017
Locations: Health ResearchTx, LLC, Trevose, Pennsylvania
Conditions: Diabetes Mellitus, Type 2
A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.
Completed
The purpose of this study is to assess the pharmacokinetics and safety of a single subcutaneously injected dose of albiglutide in subjects with type 2 diabetes mellitus with varying degrees of renal function, including subjects requiring hemodialysis.
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
07/18/2017
Locations: GSK Investigational Site, Anniston, Alabama +6 locations
Conditions: Diabetes Mellitus, Type 2
Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery
Terminated
This research is being done to see if giving a hormone called GLP-1 can improve heart function and reduce length of stay in the Cardiac Surgical Intensive Care Unit (CSICU) in people who have non-emergent coronary artery bypass graft (CABG) surgery.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/29/2017
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: CABG
A Drug Interaction Study With Albiglutide and Warfarin
Completed
This open-label study evaluates the pharmacokinetics of warfarin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of warfarin.
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
06/21/2017
Locations: GSK Investigational Site, Austin, Texas
Conditions: Diabetes Mellitus, Type 2
An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .
Completed
This study will be an open-label study to evaluate the effect of albiglutide on the pharmacokinetics and pharmacodynamics of a standard oral contraceptive regimen (Brevicon). The primary objective of this study is to demonstrate the lack of effect of albiglutide doses on the pharmacokinetics of norethindrone and ethinyl estradiol in healthy female subjects.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
06/13/2017
Locations: GSK Investigational Site, Austin, Texas
Conditions: Diabetes Mellitus, Type 2
A Drug Interaction Study of Albiglutide and Digoxin
Completed
This Phase I, open-label, sequential, single-center study evaluates the pharmacokinetics of digoxin when coadministered with albiglutide in healthy adult subjects.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/09/2017
Locations: GSK Investigational Site, Austin, Texas
Conditions: Diabetes Mellitus, Type 2
A Drug Interaction Study of Simvastatin and Albiglutide
Completed
This open-label study evaluates the pharmacokinetics of simvastatin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of simvastatin.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/07/2017
Locations: GSK Investigational Site, Austin, Texas
Conditions: Diabetes Mellitus, Type 2
The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition
Terminated
This study is being conducted to evaluate changes in sugar, metabolism, heart function and changes in body composition as patients lose weight following bariatric surgery. The investigators will compare improvements of the above changes as a function of the four different types of bariatric surgery. The investigators believe the most beneficial and safest procedure will be the Roux-en-Y.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
06/01/2017
Locations: Johns Hopkins Bayview Medical Center, Baltimore, Maryland
Conditions: Bariatric Surgery
Incretin Regulation of Insulin Secretion in Monogenic Diabetes
Completed
The purpose of this study is to explore the mechanisms of metabolic control in monogenic diabetes patients treated with sulfonylurea medications.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/06/2017
Locations: University of Chicago, Chicago, Illinois
Conditions: Monogenic Diabetes
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
Completed
This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin. Subjects who are renally impaired with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately controlled on their current regimen of diet and exercise or their antidiabetic therapy of metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetic medications will be recruited into the study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2017
Locations: GSK Investigational Site, Birmingham, Alabama +217 locations
Conditions: Diabetes Mellitus, Type 2
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
Completed
This open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2017
Locations: GSK Investigational Site, Birmingham, Alabama +173 locations
Conditions: Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
Completed
This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/21/2016
Locations: GSK Investigational Site, Birmingham, Alabama +209 locations
Conditions: Diabetes Mellitus, Type 2
37 - 48 of 61